Backbone Modifications of HLA-A2-Restricted Antigens Induce Diverse Binding and T Cell Activation Outcomes | Journal of the American Chemical Society
Development of a Humanized HLA-A2.1/DP4 Transgenic Mouse Model and the Use of This Model to Map HLA-DP4-Restricted Epitopes of HBV Envelope Protein | PLOS ONE
HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine | Journal of Hematology & Oncology | Full Text
Improved Transgenic Mouse Model for Studying HLA Class I Antigen Presentation | Scientific Reports
B-NDG HLA-A2.1 mice - Biocytogen
RCSB PDB - 1JF1: Crystal structure of HLA-A2*0201 in complex with a decameric altered peptide ligand from the MART-1/Melan-A
B-HLA-A2.1 Mice - Biocytogen
Anti-HLA-A2 PE - EXBIO Antibodies
HLA-A - Wikipedia
RCSB PDB - 1JF1: Crystal structure of HLA-A2*0201 in complex with a decameric altered peptide ligand from the MART-1/Melan-A
Distinct Polymorphisms in HLA Class I Molecules Govern Their Susceptibility to Peptide Editing by TAPBPR - ScienceDirect
Vaccines | Free Full-Text | Identification of HLA-A2-Restricted Mutant Epitopes from Neoantigens of Esophageal Squamous Cell Carcinoma
Addgene: HLA-A2.1
HLA-A2.1 (CB6F1) | Taconic Biosciences
B-hCD3E/HLA-A2.1 mice|BioMice｜Biocytogen
B-HLA-A2.1 Mice - Biocytogen
DimerX I: Recombinant Soluble Dimeric Human HLA-A2:Ig Fusion Protein
Identification of HLA-A2 or HLA-A24-restricted CTL epitopes for potential HSP105-targeted immunotherapy in colorectal cancer
HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine | Journal of Hematology & Oncology | Full Text
Backbone Modifications of HLA-A2-Restricted Antigens Induce Diverse Binding and T Cell Activation Outcomes | Journal of the American Chemical Society
B-hCD3E/HLA-A2.1 mice|BioMice｜Biocytogen
HLA Gene May Predict if Cancer Immunotherapy Will Work - NCI
HLA-A∗02-gated safety switch for cancer therapy has exquisite specificity for its allelic target antigen: Molecular Therapy - Oncolytics
Novel HLA-A2 restricted antigenic peptide derivatives with high affinity for the treatment of breast cancer expressing NY-ESO-1 - ScienceDirect
NCG-HLA-A2.1 Mouse | Charles River
